Oncolytic Therapy Adds No Survival Benefit to PD-1 Treated Advanced Melanoma
Source: Cancer Therapy Advisor, September 2021
Combining talimogene laherparepvec (T-VEC) with pembrolizumab did not lead to a survival benefit for patients with advanced melanoma.
In the phase 1b part of MASTERKEY-265, T-VEC plus pembrolizumab showed promising complete response rate (CRR) of 33% in 21 patients with advanced melanoma.
